Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer

Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer

A significant fraction of non-small cell lung cancer (NSCLC) cases are due to oncogenic mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR). Anti-EGFR antibodies have shown limited clinical benefit for NSCLC, whereas tyrosine kinase inhibitors (TKIs) are effective,...

Full description

Bibliographic Details
Main Authors: Brian J. Thomas, Caitlyn Guldenpfennig, Yue Guan, Calvin Winkler, Margaret Beecher, Michaela Beedy, Ashley F. Berendzen, Lixin Ma, Mark A. Daniels, Donald H. Burke, David Porciani
Format: Article
Language:English
Published: Elsevier 2023-12-01
Series:Molecular Therapy: Nucleic Acids
Subjects:
MT: Delivery Strategies
aptamers
non-small cell lung cancer
oligonucleotides
tumor cell-surface receptors
molecular engineering
Online Access:http://www.sciencedirect.com/science/article/pii/S2162253123002640

Similar Items

Similar Items